

# WELCOME TO UPPSALA

XV<sup>th</sup> Meeting of the European Association for Haematopathology

**Welcome to Uppsala and the XV<sup>th</sup> meeting of the European Association for Haematopathology, September 25-30, 2010, Uppsala Concert & Congress, Uppsala, Sweden**

On behalf of the Local Organizing Committee and EAHP, I am very pleased to welcome you to Uppsala for this XV<sup>th</sup> Meeting of EAHP, which is a joint venture of the European Association for Haematopathology and the Society of Hematopathology.

Previous meetings have been held in various parts of the European continent. Now for the first time, the EAHP Meeting is located in Scandinavia – very close to the middle of the Northern countries where Uppsala is situated on the map.

The general outline of the meeting follows the traditional format. It starts on Saturday with an afternoon *Educational session* with the topic 'Benign or malignant'. On Sunday, the European Bone Marrow Working Group holds a *Bone Marrow Symposium* with the topic: 'From molecular and histopathological studies to therapy'. This is followed by a *Bone Marrow Workshop* on 'Unusual acute leukemias, Transformation of MPN and MDS and Myelosarcomas and other cases'. Monday through Wednesday follows the *EAHP Lymphoma Symposium*, which covers the following topics: Early events in lymphomagenesis, Early events in B-cell neoplasms, Molecular events in Lymphomagenesis, Lymphomagenesis in T-cell neoplasms and Hodgkin lymphoma, and Recent advances in Haematopathology. The meeting ends with a 1½ day *Lymphoma Workshop* on Early lesions in lymphoid neoplasia.

Approximately 200 abstracts and about the same number of cases have been submitted to the Symposia and Workshops. This together with the generous contribution by many distinguished invited speakers and experts in the field promises that the meeting will be successful in enlightening the important topics that were chosen for this meeting. The final program thus includes oral presentations by invited speakers and authors of selected abstracts. Together with poster sessions and special satellite symposia, this program ensures that the state-of-the-art of the topics of the meeting is well covered. In addition, the workshops will present a more practically oriented perspective on the chosen issues within the 'art of haematopathology'.

It is my hope that your stay in Uppsala not only will give you a fruitful 'scientific input' but also you will have time and opportunity to see some of Uppsala's urban life and historical landmarks.

Welcome to Uppsala!



Christer Sundström  
for the Local Organizing Committee

# COMMITTEES

## XVth Meeting of the European Association for Haematopathology

### Local Organizing Committee

Christer Sundström, Chairman, Uppsala, Sweden, Department of Genetics and Pathology  
e-mail: christer.sundstrom@akademiska.se, phone: +46 18 611 38 06, mobile: +46 70 718 23 28  
Anna Porwit, Stockholm, Sweden  
Richard Rosenquist, Uppsala, Sweden  
Birgitta Sander, Stockholm, Sweden

### International Scientific Committee

Elias Campo, Barcelona, Spain  
Philippe Gaulard, Paris, France  
Martin Hansmann, Frankfurt, Germany  
Daphne de Jong, Amsterdam, The Netherlands  
Philip Kluin, Groningen, The Netherlands  
Hans Kreipe, Hannover, Germany  
Laszlo Krenacs, Szeged, Hungary  
Antoine de Mascarel, Bordeaux, France  
Stefano Pileri, Bologna, Italy  
Anna Porwit, Stockholm, Sweden  
Leticia Quintanilla-Fend, Tübingen, Germany  
Jonathan Said, Los Angeles, USA  
Christer Sundström, Uppsala, Sweden  
Andrew Wotherspoon, London, UK

### Lymphoma Abstract Review Panel

Elias Campo, Barcelona, Spain  
Philippe Gaulard, Paris, France  
Martin Hansmann, Frankfurt, Germany  
Eric Hsi, Cleveland, USA  
Daphne de Jong, Amsterdam, The Netherlands  
Philip Kluin, Groningen, The Netherlands  
Antoine de Mascarel, Bordeaux, France  
Stefano Pileri, Bologna, Italy  
Leticia Quintanilla-Fend, Tübingen, Germany  
Richard Rosenquist, Uppsala, Sweden  
Jonathan Said, Los Angeles, USA  
Birgitta Sander, Stockholm, Sweden  
Christer Sundström, Uppsala, Sweden  
Andrew Wotherspoon, London, UK

### Conference secretariat

For practical questions and registration, please contact:  
Academic Conferences  
e-mail: eahp2010@akademikonferens.uu.se, phone: +46 18 67 10 03

### Lymphoma Workshop Panel

José Cabeçadas, Lisboa, Portugal  
Falko Fend, Tübingen, Germany  
Philippe Gaulard, Paris, France  
Elaine Jaffe, Bethesda, USA  
Philip Kluin, Groningen, The Netherlands  
Isinsu Kuzu, Ankara, Turkey  
LoAnn Peterson, Chicago USA  
Christer Sundström, Uppsala, Sweden  
Andrew Wotherspoon, London, UK

### Bone Marrow Abstract Review Panel

Hans Kreipe, Hannover, Germany  
Marcus Kremer, Munich, Germany  
Laszlo Krenacs, Szeged, Hungary  
Anna Porwit, Stockholm, Sweden

### Bone Marrow Workshop Panel

Vassiliki Kaloutsis, Thessaloniki, Greece  
Hans Kreipe, Hannover, Germany  
Attilio Orazi, New York, USA  
Anna Porwit, Stockholm, Sweden  
Zbigniew Rudzki, Birmingham, UK  
Jon van der Walt, London, UK

# GENERAL INFORMATION

## XVth Meeting of the European Association for Haematopathology

### Conference venue

Uppsala Concert and Congress Hall is located in the city centre, next to the central station. Address: Vaksala Torg 1. Entrance from Storgatan and from Vaksala Torg.

### Official language

Official language of the meeting is English

### Registration and Conference secretariat

The conference secretariat will be located in the foyer on the ground floor of the venue.

#### *Opening hours:*

Saturday September 25	13.00 – 17.30
Sunday September 26	07.30 – 19.30
Monday September 27	07.00 – 16.30
Tuesday September 28	07.00 – 16.30
Wednesday September 29	07.00 – 16.30
Thursday September 30	07.30 – 13.30

Phone: +46 (18) 730 23 84 32 (available during opening hours of the conference secretariat)

### Name badges

Your name badge is your admission to the scientific sessions and to the coffee breaks and lunches. It should be worn at all times at the conference venue. Please note that your name badge is marked with the color of the scientific sessions you have registered for and therefore give you access to only those sessions.

### Presentations

Presentations should be handed in to the technician in the Main Hall at the latest in the pause before your session starts.

### Exhibition

The exhibition area will be in Hall D on the ground floor of the venue. The exhibitors are supporting the conference and we encourage you to take part in the exhibition.

### Posters

The poster area will be in Hall D on the ground floor of the venue. There are special poster sessions scheduled according to the program.

Posters for the Bone Marrow Symposium may be mounted on Sunday September 26 from 08.00 – 19.00. All posters for the Bone Marrow Symposium has to be dismantled at 19.00 Sunday September 26 at the latest.

Posters for the Lymphoma Symposium may be mounted from Monday September 27 at 08.00 – Wednesday September 29 at 16.00. All posters for the Lymphoma Symposium has to be dismantled at 16.00 Wednesday September 29 at the latest.

The organisers take no responsibility for posters that are not dismantled in time.

# GENERAL INFORMATION

## XVth Meeting of the European Association for Haematopathology

### **Internet access**

Wireless Internet access is available.

### **Coffee breaks**

Coffee and refreshments will be served at times according to the program.

Saturday September 25: Outside the Main hall, 6<sup>th</sup> floor

Sunday September 26 – Tuesday September 28: Hall D, ground floor in the exhibition

Wednesday September 29 am: Hall D, ground floor in the exhibition

Wednesday September 29 pm: Outside the Main hall, 6<sup>th</sup> floor

Thursday September 30: Outside the Main hall, 6<sup>th</sup> floor

You need your name badge as a ticket for coffee and refreshments.

### **Lunches**

Lunches will be served in Hall D on the ground floor of the venue. Lunch will be open to participants registered for scientific sessions on that particular day. Your name badge will be marked with the color of the scientific sessions you have registered for.

### **Social events**

*Welcome reception of the XVth Meeting of EAHP, Main University Building, Sunday September 26, 20.00*

Included in the conference fee. Prebooking required.

*Gala Dinner at Uppsala Castle, Tuesday September 28, 20.30*

Prebooking required

### **Banking service, currency**

Swedish Krona (SEK) is the official currency in Sweden. An exchange office (Forex) is available next to the Tourist information, Fyristorg 8. There are plenty of cash dispensers in Uppsala. Major international credit cards are accepted in most hotels, shops and restaurants.

### **Shopping in Uppsala**

Most stores in Uppsala are open 10.00-19.00 on weekdays and 10.00-17.00 on Saturdays.

Some stores are open on Sundays as well. Grocery stores usually have longer opening hours.

### **Transport to Stockholm Arlanda International Airport**

#### *Taxi*

You can pre book a taxi at Taxi Kurir (+46 18) 123 456, [www.taxikurir.se](http://www.taxikurir.se) or at Uppsala Taxi (+46 18) 100 000, [www.uppsalataxi.se](http://www.uppsalataxi.se). The price to get to Stockholm Arlanda International Airport is about SEK 435 (45 Euro). All taxis accept credit cards.

# GENERAL INFORMATION

## XVth Meeting of the European Association for Haematopathology

### *Bus*

Bus 801 runs between Uppsala Central Station and Arlanda twice/hour from about 4 am until midnight and once/hour from midnight until 4 am. The journey takes about 45 minutes and costs 100 SEK (11 Euro). You can buy your ticket from the driver (paying in SEK).

### *Train*

Trains leave Uppsala Central Station for Arlanda Airport 1-3 times/hour from 5.00 until 23.00. The journey takes 15-20 minutes and costs 95-140 SEK (10-14 Euro) if purchased in advance at Uppsala Central Station.

If you need help to get to another airport, please come to the information desk.

### **Emergency calls**

You should call 112 if anything happens which means that an ambulance, the police or the fire brigade need to be called out. 112 is a special emergency number you can call wherever you may find yourself from a fixed or a mobile telephone.

### **International calls**

Dial 00 + country code + area code + phone number.  
For example to the US 001, to Germany 0049

### **Electricity**

In Sweden the electrical voltage used is 220/230V.

### **Pharmacy**

There are several pharmacies in Uppsala. They are called 'Apotek'.

### **Medical services**

Uppsala University Hospital, Akademiska sjukhuset, is located in central Uppsala. Telephone: +46 18 611 0000. The emergency room is in Swedish called "Akuten".

### **Smoking**

Smoking is not allowed in the conference venue, nor in any other public indoor establishments such as restaurants and bars etc.

# PROGRAM AT A GLANCE

XVth Meeting of the European Association for Haematopathology

Time	Saturday 25	Sunday 26	Monday 27
07.30			<b>Meet the Professor</b>
08.00			
08.30		<b>EBMWG Bone Marrow Symposium &amp; Workshop</b>	<b>Opening Ceremony</b>
09.00			<b>EAHP Lymphoma Symposium</b>
09.30			
10.00			
10.30			
11.00			
11.30			
12.00			
12.30			
13.00			
13.30			
14.00			
14.30	<b>EAHP Educational Session</b>		
15.00			
15.30			
16.00			
16.30			
17.00			
17.30		<b>CLL &amp; MCL Satellite Symposium Sponsored by Roche</b>	
18.00			
18.30		<b>EBMWG Business Meeting</b>	
19.00			
19.30			
20.00		<b>Welcome Reception University Building</b>	
20.30			
21.00			
21.30			
22.00			
22.30			
23.00			



Educational Session





Bone Marrow Symposium & Workshop

# PROGRAM AT A GLANCE

XVth Meeting of the European Association for Haematopathology

Tuesday 28	Wednesday 29	Thursday 30	Time
<b>EAHP Lymphoma Symposium</b>	<b>Meet the Professor</b>	<b>EAHP Lymphoma Workshop</b>	07.30
			08.00
			08.30
			09.00
			09.30
			10.00
			10.30
			11.00
			11.30
			12.00
	12.30		
	13.00		
	13.30		
	14.00		
	14.30		
	15.00		
	15.30		
	16.00		
	<b>General Assembly</b>		<b>EAHP Lymphoma Workshop</b>
<b>Dako Satellite Symposium</b>	17.00		
	17.30		
<b>Gala Dinner at Uppsala Castle</b>		18.00	
		18.30	
		19.00	
		19.30	
		20.00	
		20.30	
		21.00	
		21.30	
		22.00	
		22.30	
		23.00	

 Lymphoma Symposium

 Lymphoma Workshop

# SPONSORS & EXHIBITORS

## Main sponsor



## Gold sponsors



*a member of the Roche group*

## Silver sponsors



## Exhibitors

AB Applied Biosystems

Atlas Antibodies AB

Beckman Coulter AB

Becton Dickinson

Carl Zeiss AB

Olink AB

## EAHP Educational session

XVth Meeting of the European Association for Haematopathology

Saturday, September 25 • 14.30 – 18.00

**Topic: ‘Benign or malignant?’**

Chairs: *Nancy Lee Harris & Peter Isaacson*

- 14.30 – 15.00 Morphologic and clinical features in distinguishing benign from malignant lymphoid proliferations  
*Nancy Lee Harris, Boston, MA, USA*
- 15.00 – 15.30 Immunoglobulin immunohistochemistry in distinguishing benign from malignant lymphoid proliferations  
*Peter Isaacson, London, UK*
- 15.30 – 16.00 Coffee break
- 16.00 – 16.30 Clonality testing in haematopathology: Potentials and problems  
*Han van Krieken, Nijmegen, The Netherlands*
- 16.30 – 17.00 Benign vs malignant lymphoid lesions in the skin  
*Rein Willemze, Leiden, The Netherlands*
- 17.00 – 17.30 MGUS, myeloma and amyloidosis  
*Robert McKenna, Minneapolis, MN, USA*

Sunday, September 26 • 08.30 – 15.00

## Topic: From molecular and histopathological bone marrow studies to therapy

08.30 – 08.40 **Opening**

*Anna Porwit, Stockholm, Sweden &  
Hans Kreipe, Hannover, Germany*

08.40 – 10.15 **Session 1**

*Chairs: Demi Anagnostou, Athens, Greece &  
Vito Franco, Palermo, Italy*

08.40

Review from Cleveland meeting: Plasma cell myeloma and other plasma cell neoplasms - exciting new facts about an old disease  
*Falko Fend, Tübingen, Germany*

09.15

Blasts in the bone marrow: Information from bone marrow smears, bone marrow biopsy and flow cytometry  
*Robert McKenna, Minneapolis, MN, USA*

09.45

Myeloproliferative neoplasms. Recent advances in pathogenesis  
*Andy Chase, Salisbury, Wiltshire, UK*

10.15 – 10.45 **Coffee break**

10.45 – 12.25 **Session 2**

*Chairs: Nina Hurwitz, Basel, Switzerland &  
Hans Kreipe, Hannover, Germany*

10.45

Myelodysplastic syndrome: from bone marrow studies to new therapies  
*Eva Hellström-Lindberg, Stockholm, Sweden*

11.15

Impact of new prognostic markers on treatment decisions in acute myeloid leukaemia  
*Hartmut Döhner, Ulm, Germany*

## XVth Meeting of the European Association for Haematopathology

- 11.45      Immunohistochemical and molecular detection of TP53 associated with disease progression in bone marrow of patients with low-risk myelodysplastic syndrome with del(5q)  
Leonie Saft<sup>1</sup>, Martin Jädersten<sup>2</sup>, Alexander Smith<sup>3</sup>, Austin Kulasekararaj<sup>3</sup>, Sabine Pomplun<sup>3</sup>, Robert Hast<sup>2</sup>, Anna Porwit<sup>1</sup>, Ghulam Mufti<sup>3</sup> and Eva Hellström-Lindberg<sup>2</sup>  
<sup>1</sup>Karolinska Institutet, Pathology and Oncology, Stockholm, Sweden; <sup>2</sup>Karolinska Institutet, Medicine, Center for Experimental Hematology, Stockholm, Sweden; <sup>3</sup>King's College London School of Medicine, Hematological Medicine, London, UK
- 11.55      STAT5 in BCR-ABL1- and JAK2V617F-induced MPNs  
Christoph Walz<sup>1,2</sup>, Katherine Lazarides<sup>2</sup>, Nihal Patel<sup>2</sup>, Lothar Hennighausen<sup>3</sup>, Virginia M. Zaleskas<sup>2</sup>, Richard A. Van Etten<sup>2</sup>  
<sup>1</sup>University Medical Centre Mannheim, Institute of Pathology, Mannheim, Germany; <sup>2</sup>Tufts Medical Center, Molecular Oncology Research Institute, Boston, USA; <sup>3</sup>NIH, NIDDK/Laboratory of Genetics & Physiology, Bethesda, USA
- 12.05      Characterization of the JAK-STAT and PI3K-AKT pathway in primary myelofibrosis  
Bram Geenen<sup>1</sup>, Patricia JTA Groenen<sup>1</sup>, Annemiek W Van Raaij<sup>1</sup>, Paul DM Rombout<sup>1</sup> and Konnie M Hebeda<sup>1</sup>  
<sup>1</sup>RUNMC, Pathology, Nijmegen, Netherlands
- 12.15      Chronic cold agglutinin disease (CAD) – a distinct type of lymphoproliferative disease?  
Ulla Randen<sup>1</sup>, Assia Bassarova<sup>1</sup>, Anne M Tierens<sup>1</sup>, Geir E Tjønnfjord<sup>1</sup>, Sigbjørn Berentsen<sup>2</sup>, Klaus H Beiske<sup>1</sup> and Jan Delabie<sup>1</sup>  
<sup>1</sup>Oslo University Hospital, Dept. of Pathology, Oslo, Norway; <sup>2</sup>Haugesund Hospital, Dept. of Medicine, Oslo, Norway
- 12.30 – 14.00      Lunch break
- 14.00 – 15.00      **Poster session**  
Moderators: *Marcus Kremer, Munich, Germany & Laszlo Krenacs, Szeged, Hungary*

Sunday, September 26 • 15.00 – 18.30

15.00 – 16.00 **Session 1: Unusual acute leukemias**

Chairs: *Anna Porwit, Stockholm, Sweden & Zbigniew Rudzki, Birmingham, UK*

Case presentations:

**BMW39: ACUTE MONOBLASTIC LEUKEMIA WITH T(9;11)(P22;Q23) AND +8, PRECEDED BY TRANSIENT BICYTOPENIA AND T-LYMPHOCYTOSIS IN THE BONE MARROW BIOPSY**

Esther Mueller-Garamvölgyi<sup>1</sup>, Tobias Silzle<sup>2</sup>, Joëlle Tschinda<sup>3</sup> and Peter Keller<sup>2</sup>

<sup>1</sup>University of Berne, Institute of Pathology, Bern, Switzerland; <sup>2</sup>Inselspital Bern, Hematology, Bern, Switzerland; <sup>3</sup>University Children's Hospital, Oncology, Zürich, Switzerland

**BMW 44: ACUTE MYELOMASTOCYTIC LEUKEMIA**

Sergej Konoplev<sup>1</sup>, Jianlan Sun<sup>1</sup>, Carlos Bueso-Ramos<sup>1</sup> and Jeffrey Medeiros<sup>1</sup> MD  
Anderson Cancer Center, Department of Hematopathology, Houston, TX, USA

**BMW60: THERAPY-RELATED ACUTE MYELOID LEUKEMIA (MONOBLASTIC) EPIPODOPHYLLOTOXIN-RELATED ASSOCIATED WITH T(8;16)(P11;P13); MOZ(MYST3)-CREBBP WHICH SHOWED LIKELY DIFFERENTIATION TO HISTIOCYTES AT DAY 14 OF STANDARD AML CHEMOTHERAPY**

Elizabeth Hyjek<sup>1</sup>, Yanming Zhang<sup>2</sup>, Richard A Larson<sup>3</sup>, James W Vardiman<sup>1</sup> and John Anastasi<sup>1</sup>

<sup>1</sup>University of Chicago., Department of Pathology, Hematopathology Section, Chicago, USA; <sup>2</sup>University of Chicago, Department of Medicine, Section of Hematology Oncology, Cancer Cytogenetic Laboratory, Chicago, IL, USA; <sup>3</sup>University of Chicago, Department of Medicine, Section of Hematology Oncology, Chicago, IL, USA

Cases summarized by chairpersons: BMW1, 20, 21, 22, 28, 29, 33, 35, 36, 37, 38, 40, 42, 43, 45, 46, 47, 48, 49, 51, 52, 53, 54, 61, 62

16.00 – 16.20 **Coffee break**

16.20 – 17.30 **Session 2: Transformation of MPN and MDS**

Chairs: *Attilio Orazi, New York, USA & Hans Kreipe, Hannover, Germany*

Case presentations:

**BMW17: POLYCYTHAEMIA VERA WITH UNUSUAL CHRONIC NEUTROPHILIC LEUKAEMIA-LIKE TRANSFORMATION**

Zbigniew Rudzki.

Heart of England NHS Foundation Trust, Department of Histopathology, Birmingham, UK

**BMW 31: 58 YEAR OLD MAN WITH ACUTE MYELOID BLAST PHASE OF CHRONIC MYELOGENOUS LEUKEMIA**

Katalin Kelemen,

Oregon Health Science University, Pathology, Portland, Oregon, USA

## XVth Meeting of the European Association for Haematopathology

### BMW 10: 41 YEAR OLD FEMALE WITH HISTORY OF MONOCYTOPENIA AND NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS

Katherine R Calvo<sup>1</sup>, Stefania Pittaluga<sup>2</sup>, Donald C Vinh<sup>3</sup>, Maryalice Stetler-Stevenson<sup>2</sup>, Diane Arthur<sup>4</sup>, Dennis Hickstein<sup>5</sup> and Steven M Holland<sup>3</sup>

<sup>1</sup>National Institutes of Health Clinical Center, Department of Laboratory Medicine/Hematology, Bethesda, MD, USA; <sup>2</sup>National Cancer Institute/NIH, Hematopathology/Laboratory of Pathology, Bethesda, MD, USA; <sup>3</sup>National Institute of Allergy and Infectious Diseases/NIH, Laboratory of Clinical Infectious Diseases, Bethesda, MD, USA; <sup>4</sup>National Cancer Institute/NIH, Cytogenetics, Laboratory of Pathology, Bethesda, MD, USA; <sup>5</sup>National Cancer Institute/NIH, Medical Oncology, Bethesda, MD, USA

### BMW23: PDGFRA REARRANGEMENT LEADING TO HYPER-EOSINOPHILIA, T-LYMPHOBLASTIC LYMPHOMA, MYELOPROLIFERATIVE DISORDER AND PRECURSOR B ACUTE LYMPHOBLASTIC LEUKEMIA

Qin Huang<sup>1</sup>, David Snyder<sup>2</sup>, Karl Gaal<sup>1</sup> and Karen Chang<sup>1</sup>

<sup>1</sup>City of Hope National Medical Center, Pathology, Duarte, CA, USA; <sup>2</sup>City of Hope National Medical Center, Hematology and BMT, Duarte, CA, USA

Cases summarized by chairpersons: BMW8, 9, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 30, 32, 34, 63, 64

## 17.30 – 18.30 **Session 3: Myelosarcomas and other cases**

Chairs: *Vassiliki Kaloutsi, Thessaloniki, Greece & Jon van der Walt, London, UK*

### Case presentations:

#### BMW 6: MYELOID SARCOMA. PRIMARY IN CERVIX UTERI

Nataliya Vytrva<sup>1</sup> and Anna Porwit<sup>1</sup>

<sup>1</sup>Karolinska University Hospital, Department of Pathology, Stockholm, Sweden

#### BMW 50: ACUTE MYELOID LEUKEMIA WITH A RECURRENT ISOLATED MYELOID SARCOMA OF THE TESTIS AND SUBSEQUENT CNS INVOLVEMENT.

David D Grier<sup>1</sup> and Thomas W McLean<sup>1</sup>

<sup>1</sup>Wake Forest University School of Medicine, Pathology, Winston-Salem, NC, USA

#### BMW 3: 62 YEAR OLD AFRICAN AMERICAN FEMALE WITH LYMPHADENOPATHY OF ONE MONTHS DURATION

Brian W Olsen<sup>1</sup> and Wanderly De Mendoza Calaca<sup>2</sup>

<sup>1</sup>Ingham Regional Medical Center, Dept of Pathology, Lansing, USA; <sup>2</sup>Sparrow Regional Medical Center, Dept of Pathology, Lansing, USA

Cases summarized by chairpersons: BMW2, 4, 5, 7, 24, 55, 56, 57, 58, 59

## 18.30 – 19.15 **EBMWG Business Meeting**

## 20.00 **Welcome Reception, University Building**

# EAHP Lymphoma Symposium

XVth Meeting of the European Association for Haematopathology

Monday, September 27 • 07.30 – 17.30

07.30 – 08.30 **Meet the Professor:** Early transformation to acute leukemia in bone marrow and in extramedullary sites  
*Attilio Orazi, New York, NY, USA*

08.30 – 09.00 **Opening Ceremony:** Welcome, Introductory words  
*Christer Sundström, Uppsala, Sweden*

## Topic: Early Molecular Events in Lymphomagenesis

Chairs: *Philip Kluin & Andreas Rosenwald*

09.00 – 09.45 **Key Note Lecture:** Early molecular events in lymphomagenesis  
*Bertrand Nadel, Marseille, France*

09.45 Expression of transcription factors in the proliferative compartment of follicular lymphoma  
*Karoline Koch<sup>1</sup>, Lisa Culemeyer<sup>1</sup> and Wolfram Klapper<sup>1</sup>*  
<sup>1</sup>University Hospital Schleswig-Holstein, Institute of Pathology, Hematopathology Section and Lymph Node Registry, Kiel, Germany

10.00 A common subset of splenic marginal zone lymphoma expresses antibodies with reactivity towards a similar auto-antigen  
*Abdirashid Ali Warsame*  
Radiumhospital, Oslo University Hospital, Departement of Pathology, Oslo, Norway

10.15 Differential expression of NF- $\kappa$ B target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism  
*Rifat Hamoudi<sup>1</sup>, Alex Appert<sup>1</sup>, Hongtao Ye<sup>1</sup>, Agnes Ruskone-Fourmestraux<sup>2</sup>, Berthold Streubel<sup>3</sup>, Andreas Chott<sup>3</sup>, Markus Raderer<sup>4</sup>, Liping Gong<sup>1</sup>, Iwona Wlodarska<sup>5</sup>, Christiane De Wolf-Peeters<sup>6</sup>, Kenneth A. MacLennan<sup>7</sup>, Laurence De Leval<sup>8</sup>, Peter G. Isaacson<sup>9</sup> and Ming-Qing Du<sup>1</sup>*

<sup>1</sup>University of Cambridge, Department of Pathology, Cambridge, UK; <sup>2</sup>Hôpital St Antoine, Service de Gastro-entérologie, Paris, France; <sup>3</sup>Medical University of Vienna, Department of Pathology, Vienna, Austria; <sup>4</sup>University Hospital Vienna, Department of Medicine I, Vienna, Austria; <sup>5</sup>Katholieke Universiteit Leuven, Center for Human Genetics, Leuven, Belgium; <sup>6</sup>University of Leuven, Department of Morphology and Molecular Pathology, Leuven, Belgium; <sup>7</sup>University of Leeds, Molecular Medicine Unit, St. James's University Hospital, Leeds, UK; <sup>8</sup>CHU Sart Tilman, Department of Pathology, Liège, Belgium; <sup>9</sup>University College London, Department of Histopathology, London, UK

10.30 – 11.00 Coffee break

## Topic: Early Events in B-cell neoplasms

Chairs: LoAnn Petersen & Richard Rosenquist

11.00 – 11.30 **Topic lecture:** Monoclonal B-cell lymphocytosis

*Paolo Ghia, Milano, Italy*

11.30

The spectrum of HCV-associated lymphoproliferative disorders

Manuela Mollejo<sup>1</sup>, Javier Menarguez<sup>2</sup>, Pablo Guisado-Vasco<sup>3</sup>, Patrocinio Algara<sup>4</sup>, Santiago Montes-Moreno<sup>5</sup>, Maria S Rodriguez-Pinilla<sup>5</sup>, Purificacion Dominguez<sup>6</sup>, Carlos Montalban<sup>3</sup> and Miguel A Piris<sup>5</sup>

<sup>1</sup>Hospital Virgen de la Salud, Pathology Department, Toledo, Spain; <sup>2</sup>Hospital Gregorio Marañon, Pathology Department, Madrid, Spain; <sup>3</sup>Hospital Ramon y Cajal, Department of Internal Medicine, Madrid, Spain; <sup>4</sup>Hospital Virgen de la Salud, Genetics Department, Toledo, Spain; <sup>5</sup>CNIO, Molecular Pathology Programme, Madrid, Spain; <sup>6</sup>Hospital Infanta Sofia, Pathology Department, Madrid, Spain

11.45

A higher prevalence of adverse prognostic genetic aberrations and unmutated IGH V-genes in patients with small lymphocytic lymphoma as compared to chronic lymphocytic leukemia

Patricia JTA Groenen<sup>1</sup>, Reinier Raymakers<sup>2</sup>, Paul DM Rombout<sup>1</sup>, Martijn De Prenter<sup>1</sup>, Annet Simons<sup>3</sup>, Linda Kossen<sup>3</sup>, Corine Jansen<sup>1</sup>, Ton Feuth<sup>4</sup>, Han Van Krieken<sup>1</sup> and Marian Stevens-Kroef<sup>3</sup>

<sup>1</sup>Radboud University Nijmegen Medical Centre, Pathology, Nijmegen, The Netherlands; <sup>2</sup>University Medical Centre Utrecht, Hematology, Utrecht, The Netherlands; <sup>3</sup>Radboud University Nijmegen Medical Centre, Human Genetics, Nijmegen, The Netherlands; <sup>4</sup>Radboud University Nijmegen Medical Centre, Epidemics and Statistics, Nijmegen, The Netherlands

12.00

Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B cell receptors

Millaray Marincevic<sup>1</sup>, Mahmoud Mansouri<sup>1</sup>, Meena Kanduri<sup>1</sup>, Anders Isaksson<sup>2</sup>, Hanna Göransson<sup>2</sup>, Karin Ekström Smedby<sup>3</sup>, Jesper Jurlander<sup>4</sup>, Gunnar Juliusson<sup>5</sup>, Fred Davi<sup>6</sup>, Kostas Stamatopoulos<sup>7</sup> and Richard Rosenquist<sup>1</sup>

<sup>1</sup>Uppsala University, Department of Genetics and Pathology, Uppsala, Sweden; <sup>2</sup>Cancer Pharmacology and Informatics, Uppsala University, Department of Medical Sciences, Uppsala, Sweden; <sup>3</sup>Clinical Epidemiology Unit, Karolinska Institutet, Department of Medicine, Stockholm, Sweden; <sup>4</sup>Leukemia Laboratory, Rigshospitalet, Department of Hematology, Copenhagen, Denmark; <sup>5</sup>Hematology and Transplantation, Lund University, Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund, Sweden; <sup>6</sup>Hôpital Pitié-Salpêtrière et Université Pierre et Marie, Laboratoire d'Hématologie, Paris, France; <sup>7</sup>G. Papanicolaou Hospital, Hematology Department and HCT Unit, Thessaloniki, Greece

# EAHP Lymphoma Symposium

## XVth Meeting of the European Association for Haematopathology

- 12.15 miR-182 is a candidate target of the 7q32 deletion in splenic marginal zone lymphoma and is frequently mutated in a range of lymphoma subtypes  
Alan J Watkins<sup>1</sup>, Rifat Hamoudi<sup>1</sup>, Hongxiang Liu<sup>2</sup>, Jianzhong Zhang<sup>3</sup>, Laurence De Leval<sup>4</sup>, Peter G Isaacson<sup>5</sup>, Andrew Wotherspoon<sup>6</sup> and Ming-Qing Du<sup>1</sup>

<sup>1</sup>University of Cambridge, Department of Pathology, Cambridge, United Kingdom; <sup>2</sup>Cambridge University Hospitals Trust, Department of Histopathology, Cambridge, United Kingdom; <sup>3</sup>306 Hospital, Department of Pathology, Beijing, China; <sup>4</sup>Institut Universitaire de Pathologie, Department of Pathology, Lausanne, Switzerland; <sup>5</sup>University College Hospital, Department of Histopathology, London, United Kingdom; <sup>6</sup>Royal Marsden Hospital, Department of Histopathology, London, United Kingdom

### 12.30 – 14.00 Lunch Break

Chairs: Daphne de Jong & German Ott

- 14.00 – 14.30 **Topic lecture:** 'In situ' and early follicular lymphoma  
Elaine Jaffe, Bethesda, MD, USA

- 14.30 Follicular lymphoma in situ and with partial lymph node involvement - clinical and genetical implications

P.Adam<sup>1</sup>, I. Salaverria<sup>2</sup>, M. Engelhard<sup>12</sup>, I. Bonzheim<sup>1</sup>, S. Hartmann<sup>3</sup>, H.Horn<sup>4</sup>, C. Thorns<sup>5</sup>, P. Möller<sup>6</sup>, W. Klapper<sup>7</sup>, H. Stein<sup>8</sup>, M. Dreyling<sup>9</sup>, A. Rosenwald<sup>10</sup>, M.-L.Hansmann<sup>3</sup>, G. Ott<sup>11</sup>, T. Henopp<sup>1</sup>, R. Siebert<sup>2</sup>, F. Fend<sup>1</sup>, L. Quintanilla-Martinez<sup>1</sup>

<sup>1</sup>Institute of Pathology, University of Tübingen, Germany; <sup>2</sup>Institute of Clinical Genetics, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Germany; <sup>3</sup>Institute of Pathology, Universitätsklinikum Frankfurt, Germany; <sup>4</sup>Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; <sup>5</sup>Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Germany; <sup>6</sup>Institute of Pathology, Universitätsklinikum Ulm, Germany; <sup>7</sup>Institute of Hematopathology and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Germany; <sup>8</sup>Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin, Berlin, Germany; <sup>9</sup>Department of Internal Medicine III, Universitätsklinikum der Ludwig Maximilians Universität, München-Großhadern, Germany; <sup>10</sup>Institute of Pathology, University of Würzburg, Germany; <sup>11</sup>Department of Pathology, Robert-Bosch Hospital, Stuttgart, Germany; <sup>12</sup>Department of Radiooncology, University of Essen, Germany

- 14.45 Limited stage follicular lymphoma show a very unusual spectrum of morphological and molecular features  
Patricia Gonzalez<sup>1</sup>, Olga Balagué<sup>1</sup>, Marit Roemer<sup>1</sup>, Annegien Broeks<sup>2</sup>,

## XVth Meeting of the European Association for Haematopathology

Linde Braaf<sup>2</sup>, Ron Kerkhoven<sup>3</sup>, Freek Bot<sup>4</sup>, Max Beijert<sup>5</sup> and Daphne De Jong<sup>1</sup>

<sup>1</sup>the Netherlands Cancer Institute, Pathology, Amsterdam, the Netherlands;

<sup>2</sup>the Netherlands Cancer Institute, Experimental Therapy, Amsterdam, the Netherlands; <sup>3</sup>the Netherlands Cancer Institute, Microarray Facility, Amsterdam, the Netherlands; <sup>4</sup>HAGA Hospital, Pathology, The Hague, the Netherlands; <sup>5</sup>University Medical Center Groningen, Radiation Oncology, Groningen, the Netherlands

15.00 **t(14;18) negative follicular lymphoma is characterized by downregulation of microRNAs in cell cycle control, apoptosis and B-cell differentiation**

Ellen Leich<sup>1</sup>, Elias Campo<sup>2</sup>, Randy D. Gascoyne<sup>3</sup>, Wing-Chung Chan<sup>4</sup>, Rita M. Braziel<sup>5</sup>, Lisa M. Rimsza<sup>6</sup>, Dennis D. Weisenburger<sup>4</sup>, Jan Delabie<sup>7</sup>, Elaine S. Jaffe<sup>8</sup>, Jude Fitzgibbon<sup>9</sup>, Louis M. Staudt<sup>10</sup>, Hans-Konrad Mueller-Hermelink<sup>1</sup>, Mariarita Calaminici<sup>9</sup>, German Ott<sup>11</sup>, Luis Hernandez<sup>2</sup> and Andreas Rosenwald<sup>1</sup>

<sup>1</sup>University of Würzburg, Institute of Pathology, Würzburg, Germany; <sup>2</sup>Hospital Clinic, IDIBAPS, Department of Pathology, Barcelona, Spain; <sup>3</sup>University of British Columbia, British Columbia Cancer Agency, Vancouver, Canada; <sup>4</sup>University of Nebraska Medical Center, Department of Pathology and Microbiology, Omaha, USA; <sup>5</sup>Oregon Health and Science University, Southwest Oncology Group, Portland, USA; <sup>6</sup>University of Arizona, Department of Pathology, Tucson, USA; <sup>7</sup>Norwegian Radium Hospital, Division of Pathology, Oslo, Norway; <sup>8</sup>National Cancer Institute (NCI), Laboratory of Pathology, Bethesda, USA; <sup>9</sup>St. Bartholomew's Hospital, Cancer Research UK, London, United Kingdom; <sup>10</sup>National Cancer Institute (NCI), Metabolism Branch, Bethesda, USA; <sup>11</sup>Robert-Bosch-Krankenhaus and Institute of Clinical Pharmacology, Institute of Clinical Pathology, Stuttgart, Germany

15.15 **Most t(14;18) negative follicular lymphomas are nodal marginal zone lymphomas**

J. Han J.M. Van Krieken<sup>1</sup>, Olga Balague<sup>2</sup>, Konnie Hebeda<sup>3</sup> and Daphne De Jong<sup>2</sup>

<sup>1</sup>Radboud University Nijmegen Medical Centre, Pathology, Nijmegen, Nederland; <sup>2</sup>Netherlands Cancer Institute, Pathology, Amsterdam, Netherlands; <sup>3</sup>Radboud University Nijmegen Medical Centre, Pathology, Nijmegen, the Netherlands

15.30 – 16.00 **Coffee Break**

Chairs: Eric Hsi & Birgitta Sander

16.00 – 16.30 **Topic lecture:** Early and indolent mantle cell lymphoma  
Elias Campo, Barcelona, Spain

# EAHP Lymphoma Symposium

## XVth Meeting of the European Association for Haematopathology

- 16.30** Clinical and pathologic features of indolent leukemic mantle cell lymphoma: is there a benign form of mantle cell lymphoma?  
Sarah L Ondrejka<sup>1</sup>, Raymond Lai<sup>2</sup>, Stephen D Smith<sup>3</sup> and Eric D Hsi<sup>4</sup>  
<sup>1</sup>Cleveland Clinic, Anatomic and Clinical Pathology, Cleveland, United States; <sup>2</sup>University of Alberta, Laboratory Medicine and Pathology, Edmonton, Canada; <sup>3</sup>Cleveland Clinic, Hematologic Oncology and Blood Disorders, Cleveland, United States; <sup>4</sup>Cleveland Clinic, Clinical Pathology, Cleveland, United States
- 16.45** Evidence suggesting long latency periods prior to development of mantle cell lymphoma  
Frederick K Racke<sup>1</sup>, Sabrina Simpson<sup>1</sup>, Beth Christian<sup>2</sup>, Kristie Blum<sup>2</sup> and Weiqiang Zhao<sup>1</sup>  
<sup>1</sup>The Ohio State University, Hematopathology/Pathology, Columbus, OH, USA; <sup>2</sup>The Ohio State University, Hematology and Oncology, Columbus, OH, USA
- 17.00** Differential expression of three genes identifies a subgroup of mantle cell lymphomas with a very favourable outcome  
Cristina Royo<sup>1</sup>, Alba Navarro<sup>1</sup>, Guillem Clot<sup>1</sup>, Itziar Salaverria<sup>2</sup>, Verónica Fernández<sup>1</sup>, Nicola Trim<sup>3</sup>, Pedro Jares<sup>1</sup>, Dolors Colomer<sup>1</sup>, Armando López-Guillermo<sup>1</sup>, Maria José Calasanz<sup>4</sup>, Wendy Erber<sup>3</sup>, German Ott<sup>5</sup>, Elena Hartmann<sup>6</sup>, Andreas Rosenwald<sup>6</sup>, Reinert Siebert<sup>2</sup>, Silvia Beà<sup>1</sup> and Elias Campo<sup>1</sup>  
<sup>1</sup>Hospital Clinic, Hematopathology Section, Barcelona, Spain; <sup>2</sup>University Hospital Schleswig-Holstein, Christian-Albrechts University, Kiel, Germany; <sup>3</sup>Addenbrooke's Hospital, Cambridge, UK; <sup>4</sup>University of Navarra, Pamplona, Spain; <sup>5</sup>Institut für Klinische Pharmakologie, Robert-Bosch-Krankenhaus, Stuttgart, Germany; <sup>6</sup>University of Würzburg, Würzburg, Germany
- 17.15** Identification of methylated genes associated with clinico-pathological features and prognosis in mantle cell lymphoma  
Anna Enjuanes<sup>1</sup>, Verónica Fernández<sup>1</sup>, Luíís Hernández<sup>1</sup>, Alba Navarro<sup>1</sup>, Silvia Beà<sup>1</sup>, Magda Pinyol<sup>2</sup>, Armando Lopez-Guillermo<sup>3</sup>, Andreas Rosenwald<sup>4</sup>, German Ott<sup>5</sup>, Elias Campo<sup>1</sup> and Pedro Jares<sup>1</sup>  
<sup>1</sup>Hospital Clínic - IDIBAPS, University of Barcelona, Hematopathology Section, Department of Pathology, Barcelona, Spain; <sup>2</sup>Hospital Clínic - IDIBAPS, University of Barcelona, Genomics Unit, Barcelona, Spain; <sup>3</sup>Hospital Clínic - IDIBAPS, University of Barcelona, Department of Hematology, Barcelona, Spain; <sup>4</sup>University of Würzburg, Institute of Pathology, Würzburg, Germany; <sup>5</sup>Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Department of Clinical Pathology, Stuttgart, Germany
- 17.30** End of the Session

XVth Meeting of the European Association for Haematopathology

18.00 – 19.30 **CLL & MCL – a Nordic perspective**  
- Satellite Symposium sponsored by Roche



Chair: *Eva Kimby, Stockholm, Sweden*

- 18.00 Welcome  
*Eva Kimby, Stockholm, Sweden*
- 18.10 Prognostic factors in chronic lymphocytic leukemia  
*Richard Rosenquist, Uppsala, Sweden*
- 18.30 Antigens in chronic lymphocytic leukemia pathogenesis  
*Anders Rosén, Linköping, Sweden*
- 18.50 The impact of SOX11 on mantle cell lymphoma biology  
*Sara Ek, Lund, Sweden*
- 19.10 Nordic treatment strategies in mantle cell lymphoma  
*Christian Geisler, Copenhagen, Denmark*

# EAHP Lymphoma Symposium

XVth Meeting of the European Association for Haematopathology

Tuesday, September 28 • 07.30 – 17.30

07.30 – 08.30 **Meet the professor:**

Lymphoproliferative lesions of immune deficient individuals  
*Han van Krieken, Nijmegen, The Netherlands*

## Topic: Molecular Events in Lymphomagenesis

Chairs: *Elias Campo & Elaine Jaffe*

08.30 – 09.00 **Clinical Key Note Lecture:**

Clinical impact of early lymphoma lesions  
*Eva Kimby, Stockholm, Sweden*

09.00 – 09.30 **Topic lecture:** Genetic and epigenetic alterations in lymphomas  
*Reiner Siebert, Kiel, Germany*

Chairs: *Margarita Genova & Andrew Wotherspoon*

09.30

Burkitt lymphoma can be distinguished from diffuse large B-cell lymphoma by quantitative real time-PCR

*Ria Winkelmann<sup>1</sup>, Matthias Frank<sup>1</sup>, Christian Kohler<sup>2</sup>, Rainer Spang<sup>3</sup>, Matteo Pardo<sup>4</sup>, Hilmar Berger<sup>5</sup>, Markus Kreuz<sup>5</sup>, Christoph Thorns<sup>6</sup>, Stefan Bentink<sup>7</sup>, Heinz-Wolfram Bernd<sup>8</sup>, Sergio Cogliatti<sup>9</sup>, Dirk Hasenclever<sup>5</sup>, Michael Hummel<sup>10</sup>, Wolfram Klapper<sup>11</sup>, German Ott<sup>12</sup>, Christiane Pott<sup>13</sup>, Reiner Siebert<sup>14</sup>, Benjamin Stürzenhofecker<sup>15</sup>, Lorenz Trümper<sup>16</sup> and Martin-Leo Hansmann<sup>1</sup>*

<sup>1</sup>Goethe University Frankfurt am Main, Institute of Pathology, Frankfurt am Main, Germany; <sup>2</sup>University of Regensburg, Institute of Functional Genomics Computational Diagnostics, Regensburg, Germany; <sup>3</sup>University of Regensburg, Institute for Functional Genomics Computational Diagnostics Group, Regensburg, Germany; <sup>4</sup>Max Planck Institute for Molecular Genetics, Computational Molecular Biology Dept, Berlin, Germany; <sup>5</sup>Universität Leipzig, Institut fuer medizinische Informatik, Statistik und Epidemiologie (IMISE), Leipzig, Germany; <sup>6</sup>University-Hospital Schleswig-Holstein, Campus Lübeck, Institute of Pathology, Lübeck, Germany; <sup>7</sup>Dana-Farber Cancer Institute, Department of Biostatistics and Computational Biology, Boston, USA; <sup>8</sup>Universität zu Lübeck, Institute of Pathology, Lübeck, Germany; <sup>9</sup>Kantonsspital St. Gallen, Institute of Pathology, St. Gallen, Schweiz; <sup>10</sup>Charité, Institute of Pathology, Berlin, Germany; <sup>11</sup>University-Hospital Schleswig-Holstein, Hematopathology Section and Lymph Node Registry Kiel, Kiel, Germany; <sup>12</sup>Universität Würzburg, Institute of Pathology, Würzburg, Germany; <sup>13</sup>University-Hospital Schleswig-Holstein, Campus Kiel, Second Medical Department, Kiel, Germany; <sup>14</sup>Universitätsklinikum Schleswig-Holstein, Campus Kiel, Institute of Human Genetics, Kiel, Germany; <sup>15</sup>Georg-August Universität Göttingen, Department for Hematology and Oncology, Göttingen, Germany; <sup>16</sup>Universitäts-Krebszentrum Göttingen - CCC, Abteilung Hämatologie und Onkologie, Göttingen, Germany

## XVth Meeting of the European Association for Haematopathology

- 09.45 HSA-MIR9\* as a potential candidate for *MYC* over-expression in Burkitt lymphoma cases lacking *MYC* translocation  
Anna Onnis<sup>1</sup>, Giulia De Falco<sup>1</sup>, Giuseppina Antonicelli<sup>1</sup>, Mohsen Navari<sup>1</sup>, Monica Onorati<sup>1</sup>, Cristiana Bellan<sup>1</sup>, Stefano Lazzi<sup>1</sup> and Lorenzo Leoncini<sup>1</sup>  
<sup>1</sup>University of Siena, Department of Human Pathology and Oncology, Siena, Italy
- 10.00 EBV-positive diffuse large B cell lymphoma of the elderly is a post germinal center B cell neoplasm characterized by NFkB pathway activation and *BCL2* overexpression. Evaluation of a series of 48 cases.  
Santiago Montes-Moreno<sup>1</sup>, Julio Alexander Diaz Perez<sup>1</sup>, Raquel Pajares<sup>2</sup>, Lydia Sanchez-Verde<sup>2</sup>, Juan Fernando García<sup>3</sup>, Manuela Mollejo<sup>4</sup>, Carmen Ruiz Marcellán<sup>5</sup>, Magdalena Adrados<sup>6</sup>, Nazario Ortiz<sup>7</sup>, Renato Franco<sup>8</sup>, Javier Menarguez<sup>9</sup> and Miguel Angel Piris Pinilla<sup>1</sup>  
<sup>1</sup>Spanish National Cancer Center, Lymphoma Group, Molecular Pathology Program, Madrid, Spain; <sup>2</sup>Spanish National Cancer Center, Histology and Immunohistochemistry Unit, Madrid, Spain; <sup>3</sup>MD Anderson Clinical Cancer Center, Pathology Department, Madrid, Spain; <sup>4</sup>Hospital Virgen de la Luz, Pathology Department, Toledo, Spain; <sup>5</sup>Hospital Vall d'Hebrón, Pathology Department, Barcelona, Spain; <sup>6</sup>Hospital Clínico Universitario La Princesa, Pathology Department, Madrid, Spain; <sup>7</sup>Hospital Santa Rosa, Pathology Department, Lima, Perú; <sup>8</sup>Instituto di Tumori G Pascale, Pathology Department, Napoli, Madrid; <sup>9</sup>Hospital General Universitario Gregorio Marañón, Pathology Department, Madrid, Spain
- 10.15 Identification of a non-EBV-related gene expression profile, differentiating monomorphic B-cell posttransplant lymphoproliferative disorder from diffuse large B-cell lymphoma  
Thomas Tousseyn<sup>1</sup>, Peter Van Loo<sup>2</sup>, Daan Dierickx<sup>3</sup>, Gregor Verhoef<sup>3</sup> and Christiane De Wolf-Peters<sup>1</sup>  
<sup>1</sup>University Hospitals KULeuven, Morphology and Molecular Pathology Section, Leuven, Belgium; <sup>2</sup>KULeuven, Human Genome Laboratory, Leuven, Belgium; <sup>3</sup>University Hospitals KULeuven, Hematology Section, Leuven, Belgium
- 10.30 – 11.00 **Key Note Lecture:**  
Role of inflammation and autoimmunity in lymphoma  
*Lars Klareskog, Stockholm, Sweden*
- 11.00 – 11.30 Coffee break

# EAHP Lymphoma Symposium

XVth Meeting of the European Association for Haematopathology

Chair: Philip Kluin

11.30 – 12.30 **Karl Lennert Lecture:**

*Hans Konrad Müller-Hermelink, Würzburg, Germany*

12.30 – 14.00 Lunch Break

**Topic: Lymphomagenesis in T-cell neoplasms**

Chairs: Philippe Gaulard & Isinsu Kuzu

14.00 – 14.30 **Topic lecture:** Early lymphomagenesis in T-cell neoplasms  
Ahmet Dogan, Rochester, USA

14.30 Hydroa vacciniforme (HV) like T-cell lymphoma and hypersensitivity to mosquito bites (HMB). A case series of 19 Mexican children

Florian Nagl<sup>1</sup>, Georgia Alderete<sup>2</sup>, Daniel Carrasco<sup>2</sup>, Cecilia Ridaura<sup>2</sup>, Marimar Sáez-de-Ocariz<sup>3</sup>, Carola Durán-McKinster<sup>3</sup>, Carmen Lome-Maldonado<sup>4</sup>, Irina Bonzheim<sup>1</sup>, Falko Fend<sup>1</sup> and Leticia Quintanilla-Martinez<sup>1</sup>

<sup>1</sup>University of Tuebingen, Institute of Pathology, Tuebingen, Germany; <sup>2</sup>Instituto Nacional de Pediatría, Pathology Department, Mexico City, Mexico; <sup>3</sup>Instituto Nacional de Pediatría, Dermatology Department, Mexico City, Mexico; <sup>4</sup>Instituto Nacional de la Nutrición, Pathology Department, Mexico City, Mexico

14.45 Peripheral T-cell lymphoma: integrated genomic analysis reveals new features

Socorro María Rodríguez-Pinilla<sup>1</sup>, Magda Wozniak<sup>1</sup>, María Elena Rodríguez<sup>1</sup>, Manuela Mollejo<sup>2</sup>, Francisco Javier Alves-Ferreira<sup>3</sup> and Miguel Ángel Piris<sup>1</sup>

<sup>1</sup>CNIO, Molecular Pathology Department, Lymphoma Group, Madrid, Spain; <sup>2</sup>Pathology Department, Hospital Virgen de la Salud de Toledo, Toledo, Spain; <sup>3</sup>Hospital Universitario La Paz, Pathology Department, Madrid, Spain

15.00 Gene expression profiling reveals a distinct molecular signature for hepatosplenic T-cell lymphoma

Marion Travert<sup>1</sup>, Yenlin Huang<sup>1</sup>, Aurelien De Rényies<sup>2</sup>, Laurence De Leval<sup>3</sup>, Nadine Martin-Garcia<sup>1</sup>, Françoise Berger<sup>4</sup>, Josette Brière<sup>5</sup>, Jean Soulier<sup>6</sup>, Christian Bastard<sup>7</sup>, Elizabeth MacIntyre<sup>8</sup>, Teresa Marafioti<sup>9</sup> and Philippe Gaulard<sup>1</sup>

<sup>1</sup>Hôpital Henri Mondor, Department of Pathology & Inserm U955, Créteil, France; <sup>2</sup>Ligue Nationale contre le Cancer, Ligue Nationale contre le Cancer, Paris, France; <sup>3</sup>Centre Hospitalier Universitaire Vaudois, Institute of Pathology, Lausanne, Switzerland; <sup>4</sup>Hôpital Lyon Sud, Pathology, Pierre Bénite, France; <sup>5</sup>Hôpital Saint Louis, Pathology, Paris, France; <sup>6</sup>Hôpital Saint Louis, Haematology, Paris, France; <sup>7</sup>Centre Henri Becquerel, Cytogenetics, Rouen, France; <sup>8</sup>Hôpital Nexker Enfants-Malades, Haematology, Paris, France;

<sup>9</sup>University College London, Histopathology, London, UK

- 15.15 Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma  
Lise Mette R Gjerdrum<sup>1</sup>, Maria R Kamstrup<sup>2</sup>, Edyta Biskup<sup>2</sup>, Britt T Lauenborg<sup>3</sup>, Elisabeth Ralfkiær<sup>1</sup>, Anders Woetmann<sup>4</sup>, Niels Ødum<sup>4</sup> and Robert Gniadecki<sup>2</sup>  
<sup>1</sup>Rigshospitalet, Department of Pathology, Copenhagen, Denmark; <sup>2</sup>Bispebjerg Hospital, Department of Dermatology, Copenhagen, Denmark; <sup>3</sup>University of Copenhagen, Institute of Medical Microbiology and Immunology, Copenhagen, Denmark; <sup>4</sup>Copenhagen University, Institute of Medical Microbiology and Immunology, Copenhagen, Denmark

15.30 – 16.00 Coffee Break

## Topic: Lymphomagenesis in Hodgkin lymphoma

Chairs: José Cabeçadas & Miguel Piris

- 16.00 – 16.30 **Topic lecture:** Early lymphomagenesis in Hodgkin lymphoma  
Martin L Hansmann, Frankfurt, Germany

- 16.30 Follicular peripheral T-cell lymphoma can mimic classical Hodgkin lymphoma  
Christiane Copie-Bergman<sup>1</sup>, Julien Moroch<sup>2</sup>, Teresa Marafioti<sup>3</sup>, Anne Plonquet<sup>4</sup>, Nadine Martin-Garcia<sup>5</sup>, Marie-Hélène Delfau-Larue<sup>6</sup>, Valérie Molinier-Frenkel<sup>6</sup>, Karim Belhadj<sup>7</sup>, Corinne Haiou<sup>7</sup>, Jacques Chasles<sup>8</sup>, Josée Audouin<sup>9</sup>, Laurence De Leval<sup>10</sup> and Philippe Gaulard<sup>11</sup>  
<sup>1</sup>Hôpital Henri Mondor, Dept of Pathology & Inserm U955, Créteil, France; <sup>2</sup>Hôpital Henri Mondor, Department of Pathology & Inserm U955, Créteil, France; <sup>3</sup>University College London, Histopathology, London, UK; <sup>4</sup>Hôpital Henri Mondor, Dept of Immunology & Inserm U955, Créteil, France; <sup>5</sup>Hôpital Henri Mondor, Pathology & Inserm U955, Créteil, France; <sup>6</sup>Hôpital Henri Mondor, Immunology & Inserm U955, Créteil, France; <sup>7</sup>Hôpital Henri Mondor, Haematology, Créteil, France; <sup>8</sup>Centre Régional de Lutte Contre le Cancer, Pathology, Caen, France; <sup>9</sup>Hotel Dieu, Pathology, Paris, France; <sup>10</sup>Centre Hospitalier Universitaire Vaudois, Institute of Pathology, Lausanne, Switzerland; <sup>11</sup>Hôpital Henri Mondor, Pathology & Inserm U955, Créteil, France

- 16.45 Detection of BCL6 amplification by “fiction” (combined immunofluorescence/FISH) extends the spectrum of molecular abnormalities associated with nodular lymphocyte predominant Hodgkin lymphoma  
Alexei G. Bakhirev, MD<sup>1</sup>, Mohammad A. Vasef, MD<sup>1</sup>, Qian-Yun Zhang, MD, PhD<sup>1</sup>, Kaari K. Reichard, MD<sup>1</sup> and David R. Czuchlewski, MD<sup>1</sup>  
<sup>1</sup>University of New Mexico, Department of Pathology, Albuquerque, USA

# EAHP Lymphoma Symposium

## XVth Meeting of the European Association for Haematopathology

17.00 Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma  
Franziska C Eberle<sup>1</sup>, Jaime Rodriguez-Canales<sup>1</sup>, Lai Wei<sup>2</sup>, Jeffrey C Hanson<sup>1</sup>, J Keith Killian<sup>3</sup>, Hong-Wei Sun<sup>4</sup>, Lisa G Adams<sup>1</sup>, Stephen M Hewitt<sup>1</sup>, Wyndham H Wilson<sup>5</sup>, Stefania Pittaluga<sup>1</sup>, Paul S Meltzer<sup>3</sup>, Louis M Staudt<sup>5</sup>, Michael R Emmert-Buck<sup>1</sup> and Elaine S Jaffe<sup>1</sup>  
<sup>1</sup>NIH, National Cancer Institute, Laboratory of Pathology, Bethesda, USA; <sup>2</sup>NIH, National Eye Institute, Laboratory of Immunology, Bethesda, USA; <sup>3</sup>NIH, National Cancer Institute, Genetics Branch, Bethesda, USA; <sup>4</sup>NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Biodata Mining and Discover Section, Bethesda, USA; <sup>5</sup>NIH, National Cancer Institute, Metabolism Branch, Bethesda, USA

17.15 miRNA expression signatures with prognostic significance in advanced classical Hodgkin lymphoma  
Juan F Garcia<sup>1</sup>, Beatriz Sánchez-Espiridión<sup>2</sup>, María E Rodríguez<sup>2</sup>, Miguel Canales<sup>3</sup>, Francisco J Alvés<sup>4</sup>, Francisco Vega-Vazquez<sup>5</sup>, Manuel M Morente<sup>6</sup>, José F Tomás<sup>7</sup>, Carlos Montalbán<sup>8</sup>, Pablo Guisado<sup>8</sup> and Miguel A Piris<sup>2</sup>  
<sup>1</sup>M.D. Anderson International, España, Pathology Dept., Madrid, Spain; <sup>2</sup>Spanish National Cancer Research Centre (CNIO), Lymphoma Group, Madrid, Spain; <sup>3</sup>Hospital La Paz, Hematology Dept, Madrid, Spain; <sup>4</sup>Hospital La Paz, Pathology Dept., Madrid, Spain; <sup>5</sup>M. D. Anderson Cancer Center, Hematopathology, Houston, USA; <sup>6</sup>Spanish National Cancer Research Centre (CNIO), Tumor Bank, Madrid, Spain; <sup>7</sup>M.D. Anderson International, España, Hematology Dept., Madrid, Spain; <sup>8</sup>Hospital Ramón y Cajal, Internal Medicine, Madrid, Spain

17.35 – 18.00 **EAHP General Assembly**

18.05 – 19.30 **Dako Satellite Symposium**



**Topic: Hematopathology is an integral part of the  
hematology patient management**

[Wine and snacks will be served before the meeting]

Moderator: *Elias Campo, Barcelona, Spain*

18.05

Welcome

*Elias Campo, Barcelona, Spain*

18.20

Impact of interphase FISH for the management of follicular and aggressive B cell lymphoma

*Christiane Copie-Bergman & Philippe Gaulard, Paris, France*

18.40

WHO Guidelines for myeloid leukemias – focus on application and diagnostic relevance for nucleophosmin (NPM)

*Brunangelo Falini, Perugia, Italy*

19.00

PAX5 and PAX2 distribution in normal animal and human tissues and human tumors

*Stefano Pileri & Claudio Agostinelli, Bologna, Italy*

19.20

Discussion and closing

*Elias Campo*

20.30

**Gala Dinner at Uppsala Castle**

# EAHP Lymphoma Symposium

XVth Meeting of the European Association for Haematopathology

Wednesday, September 29 • 07.30 – 13.00

07.30 – 08.30 **Meet the Professor:** The use and abuse of atypical lymphoid hyperplasia  
*Randy Gascoyne, Vancouver, Canada*

## **Topic: Recent Advances in Haematopathology**

Chairs: *Teresa Marafioti & Stefano Pileri*

08.30 – 09.00 **Key Note Lecture:**  
New antibodies: The human protein atlas project  
*Fredrik Pontén, Uppsala, Sweden*

09.00 – 09.30 **Key Note Lecture:**  
Diagnostic imaging of proteins and their interactions in pathology  
*Ulf Landegren, Uppsala, Sweden*

09.30 Biological signature of activated B cell receptor signaling in diffuse large B-cell lymphoma  
Agata M. Bogusz<sup>1</sup>, Linfeng Chen<sup>2</sup>, Treeve Currie<sup>1</sup>, Margaret A. Shipp<sup>2</sup>, Scott J. Rodig<sup>1</sup> and Jeffery L. Kutok<sup>1</sup>  
<sup>1</sup>Brigham and Women's Hospital, Department of Pathology, Boston, MA 02115, USA; <sup>2</sup>Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02115, USA

09.45 miRNA expression profiles in pediatric T lymphoblastic leukemia/lymphoma  
Magdalena Czader<sup>1</sup>, Sandeep S Dave<sup>2</sup>, Cassandra Jacobs<sup>2</sup>, Kathryn Rizzo<sup>1</sup>, Gail H Vance<sup>3</sup>, Anupama Tewari<sup>1</sup>, Sharath Bhagavathi<sup>1</sup>, Joseph Olczyk<sup>4</sup> and Mehdi Nassiri<sup>1</sup>  
<sup>1</sup>Indiana University, Department of Pathology and Laboratory Medicine, Indianapolis, USA; <sup>2</sup>Duke University, Duke Institute for Genome Sciences and Policy, Durham, USA; <sup>3</sup>Indiana University, Department of Medical and Molecular Genetics, Indianapolis, USA; <sup>4</sup>Miller School of Medicine/University of Miami, Department of Pathology, Miami, USA

## XVth Meeting of the European Association for Haematopathology

10.00 Identification of genes that play a crucial role in C/EBP $\beta$  downstream signalling in ALK+ ALCL  
Irina Bonzheim<sup>1</sup>, Martin Irmeler<sup>2</sup>, Nataša Anastasov<sup>3</sup>, Margit Klier-Richter<sup>1</sup>, Sabine Schäfer<sup>1</sup>, Patrick Adam<sup>1</sup>, Falko Fend<sup>1</sup> and Leticia Quintanilla-Martinez<sup>1</sup>  
<sup>1</sup>Institute of Pathology, University Hospital Tübingen, Eberhard-Karls-University, Tübingen, Germany; <sup>2</sup>Experimental Genetics, Helmholtz Center Munich - German Research Center for Environmental Health, Neuherberg, Germany; <sup>3</sup>Radiation Biology, Helmholtz Center Munich - German Research Center for Environmental Health, Neuherberg, Germany

10.15 Blastic plasmacytoid dendritic cell neoplasm: clinico-pathologic analysis and genome-wide array comparative genomic hybridization in 12 cases  
Marco Lucioni<sup>1</sup>, Emilio Berti<sup>2</sup>, Francesca Novara<sup>3</sup>, Roberta Riboni<sup>1</sup>, Giacomo Fiandrino<sup>4</sup>, Luca Arcaini<sup>5</sup>, Emanuela Boveri<sup>1</sup>, Marta Nicola<sup>4</sup>, Mario Lazzarino<sup>5</sup>, Orsetta Zuffardi<sup>3</sup> and Marco Paulli<sup>4</sup>  
<sup>1</sup>Foundation IRCCS Policlinico San Matteo, Anatomic Pathology, Pavia, Italy; <sup>2</sup>University of Milano Bicocca, Dermatology, Milano, Italy; <sup>3</sup>University of Pavia, Human Genetics, Pavia, Italy; <sup>4</sup>University of Pavia, Anatomic Pathology, Pavia, Italy; <sup>5</sup>University of Pavia, Hematology, Pavia, Italy

10.30 – 11.00 Coffee Break

11.00 – 12.15 **Poster Session Discussion and Poster Award**  
Moderators: *Laurence de Leval, Lausanne, Switzerland, Stefano Pileri, Bologna, Italy & Leticia Quintanilla-Fend, Tübingen Germany*

Chair: *Christer Sundström*

12.15 – 13.00 **Highlight “David Y Mason” Lecture:**  
Impact of whole genome sequencing on human cancer  
*Peter Campbell, Cambridge, UK*

13.00 – 14.30 Lunch Break

## Topic: Early lesions in lymphoid neoplasia

Wednesday, September 29 • 14.30 – 19.00

14.30 – 16.30 **Session 1: Follicular hyperplasia, progressively transformed GC and marginal zone hyperplasia**

Chairs: *Christer Sundström & Philip Kluin*

### Session 1:1: Progressively transformed germinal centers

Case presentations:

LW71: FLORID FOLLICULAR HYPERPLASIA WITH PROGRESSIVE TRANSFORMATION OF GERMINAL CENTERS

Aashiyana F Koreishi<sup>1</sup> and Julie Teruya-Feldstein<sup>2</sup>

<sup>1</sup>University of Washington Medical Center, Pathology, Seattle, WA, USA;

<sup>2</sup>Memorial Sloan Kettering Cancer Center, Pathology, New York, NY, USA

LW12: FLORID FOLLICULAR HYPERPLASIA WITH PROGRESSIVE TRANSFORMATION OF GERMINAL CENTERS WITH FOCAL NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA

Kai Zhang<sup>1</sup>

<sup>1</sup>Geisinger Health System, Geisinger Medical Laboratory, Danville, PA, United States

Cases discussed by chairpersons: LW37, 60, 64, 84

### Session 1:2 : Follicular hyperplasia and lymphoma

Case presentation:

LW19: FOLLICULAR HYPERPLASIA WITH ATYPICAL PHENOTYPIC FEATURES

Sophia L Yohe<sup>1</sup> and Robert W McKenna<sup>1</sup>

<sup>1</sup>University of Minnesota, Laboratory Medicine and Pathology, Minneapolis, United States

Cases discussed by chairpersons: LW36.2, 45, 92.4

### Session 1:3: Marginal zone lesions

Case presentations:

LW76.2: MONOCYTOID B-CELL HYPERPLASIA IN PROGRESSIVE TRANSFORMATION OF GERMINAL CENTER

Bob Roshanak<sup>1</sup>

<sup>1</sup>Charite Universitätsmedizin Berlin, Institut für Pathologie, Campus Benjamin Franklin, Berlin, Germany

## XVth Meeting of the European Association for Haematopathology

### LW18: MONOCLONAL MARGINAL ZONE HYPERPLASIA ASSOCIATED WITH HCV-INFECTION

Manuela Mollejo<sup>1</sup>, Maria S Rodriguez-Pinilla<sup>2</sup> and Miguel A Piris<sup>2</sup>

<sup>1</sup>Hospital Virgen de la Salud, Pathology, Toledo, Spain; <sup>2</sup>Spanish National Cancer Research Centre (CNIO), Molecular Pathology Programme, Madrid, Spain

Cases discussed by chairpersons: LW28,1, 28.2, 35, 29, 30, 56.1, 72, 9, 77

### Session 1:4: Hyperplasia with monotypic cells

#### Case presentation:

### LW50: MUCOSA ASSOCIATED LYMPHOID TISSUE WITH ATYPICAL LYMPHOID HYPERPLASIA AND IMMUNOGLOBULIN LIGHT CHAIN RESTRICTION

Prabhjot Kaur<sup>1</sup> and Norman Levy<sup>2</sup>

<sup>1</sup>Dartmouth-Hitchcock Medical Center, Pathology, Lebanon, USA; <sup>2</sup>Dartmouth Hitchcock Medical Center, Pathology, Lebanon, USA

Cases discussed by chairpersons: LW78.3, 62.1, 73, 22.2, 16

16.30 – 16.50 Coffee break

16.50 – 19.00 **Session 2: Monoclonal B lymphocytosis, indolent mantle cell lymphoma and early/indolent plasma cell proliferations: Diagnosis in peripheral blood, bone marrow, and other sites**  
Chairs: *LoAnn Peterson & Andrew Wotherspoon*

### Session 2:1: Persistent polyclonal lymphocytosis

#### Case presentation:

### LW5: POLYCLONAL LYMPHOCYTOSIS WITH MASSIVE SPLENOMEGALY Miguel A Piris<sup>1</sup>, Jose M Bosch<sup>2</sup>, Valeria Peri<sup>2</sup> and Luis A Martin<sup>3</sup>

<sup>1</sup>CNIO, Molecular Pathology, Madrid, Spain; <sup>2</sup>Complejo Hospitalario Materno Insular, Haematology, Las Palmas de Gran Canaria, Spain; <sup>3</sup> Complejo Hospitalario Materno Insular, Pathology, Las Palmas de Gran Canaria, Spain

Case discussed by chairpersons: LW7

### Session 2:2: Monoclonal B-cell lymphocytosis

#### Case presentations:

### LW93.1: A 47-YEAR-OLD MAN WITH A CERVICAL LYMPH NODE DISSECTION FOR PAPILLARY THYROID CANCER

Nancy Lee Harris<sup>1</sup> and Robert P. Hasserjian<sup>1</sup>

<sup>1</sup>Mass General Hospital, Pathology, Boston, USA

## XVth Meeting of the European Association for Haematopathology

LW2: SMALL B-CELL LYMPHOMA WITH UNUSUAL GROWTH PATTERN

Steven H Swerdlow<sup>1</sup>

<sup>1</sup>University of Pittsburgh School of Medicine, Division of Hematopathology, Pittsburgh, PA, USA

LW52: LYMPH NODE EQUIVALENT OF MONOCLONAL B-CELL LYMPHOCYTOSIS, CLL TYPE?

Sarah E Gibson<sup>1</sup>

<sup>1</sup>University of Pittsburgh School of Medicine, Hematopathology, Pittsburgh, USA

Cases discussed by chairpersons: LW3, 14, 23, 27, 42, 51, 99

### Session 2:3: Indolent mantle cell lymphoma

Case presentation:

LW78.1: MANTLE CELL LYMPHOMA, SMALL CELL VARIANT

Elias Campo<sup>1</sup>, Veronica Fernandez<sup>2</sup>, Alba Navarro<sup>1</sup> and Lluís Bernardo<sup>3</sup>

<sup>1</sup>Hospital Clinic, University of Barcelona, Hematopathology Unit, Anatomic Pathology, Barcelona, Spain; <sup>2</sup>Hospital Clinic, University of Barcelona, Hematopathology Unit, Barcelona, Spain; <sup>3</sup>Hospital Josep Trueta, Anatomic Pathology, Girona, Spain

Cases discussed by chairpersons: LW21.1, 31

### Session 2.4: Early/indolent plasma cell proliferations

Case presentation:

LW89: 57 YEAR OLD MAN WITH HIV AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE.

Brett M Mahon<sup>1</sup>, Arash Mohtashamian<sup>1</sup> and LoAnn Peterson<sup>1</sup>

<sup>1</sup>Northwestern Memorial Hospital, Hematopathology, Chicago, United States

LW22.3: ATYPICAL INTERFOLLICULAR IGA-KAPPA-RESTRICTED PLASMA CELL PROLIFERATION

Gunjan Gupta<sup>1</sup>, Bachir Alobeid<sup>1</sup>, Govind Bhagat<sup>1</sup> and Kar Fai Chow<sup>1</sup>

<sup>1</sup>Columbia University, Department of Pathology, New York, United States

Cases discussed by chairpersons: LW14, 39, 92.2

## Thursday, September 30 • 08.00 – 16.30

### 08.00 – 10.30 **Session 3: *In situ* Follicular lymphoma and mantle cell lymphoma: Definitions and boundaries**

Chairs: Falko Fend & Elaine Jaffe

#### Session 3:1: *In situ* follicular lymphoma

Case presentations:

LW33.2: FOLLICULAR LYMPHOMA *IN SITU* WITH FOLLOW-UP AND REPEAT BIOPSY

Patrick Adam<sup>1</sup>

<sup>1</sup>Eberhard-Karls-University of Tuebingen, Institute of Pathology, Tuebingen, Germany

LW67.1: PARTIAL NODAL INVOLVEMENT BY FOLLICULAR LYMPHOMA

Margaret Ashton-Key<sup>1</sup>

<sup>1</sup>Southampton University Hospitals, Cellular Pathology, Southampton, United Kingdom

LW49: DIFFUSE LARGE B-CELL LYMPHOMA AND *IN SITU* FOLLICULAR LYMPHOMA

Pedro Farinha<sup>1</sup>

<sup>1</sup>Centro Hospitalar Lisboa Central, Anatomia Patologica, Lisboa, Portugal

LW83: INTESTINAL FOLLICULAR LYMPHOMA WITH LYMPHOMATOUS POLYPOSIS

Andreas Chott<sup>1</sup>

<sup>1</sup>Wilhelminenspital, Pathology, Vienna, Austria

Cases discussed by chairpersons: LW74, 22.1, 17, 25, 38.1, 38.2, 38.3, 68, 44, 46, 56.2, 57, 63.1, 63.2, 85.1, 91.1, 91.2, 103

#### Session 3:2: *In situ* mantle cell lymphoma and composite lymphomas with *in situ* MCL component

Case presentations:

LW4: COMPOSITE *IN SITU* LYMPHOMAS – COEXISTENCE OF BOTH FOLLICULAR AND MANTLE CELL LYMPHOMA *IN SITU*

Michele R Roulet<sup>1</sup> and Adam Bagg<sup>2</sup>

<sup>1</sup>.Pathology Sciences Medical Group/Eastern Virginia Medical School, Department of Pathology, Norfolk, VA, USA; <sup>2</sup>.Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, PA, USA

### LW43.2: *IN SITU* MANTLE CELL LYMPHOMA

Viera Nelson<sup>1</sup>, Patrick Browne<sup>1</sup> and Bharat N Nathwani<sup>2</sup>

<sup>1</sup>Genzyme Genetics, Hematopathology, Los Angeles, USA; <sup>2</sup>Cedars-Sinai Medical Center & University of Southern California, Hematopathology, Los Angeles, USA

### LW85.2: *IN SITU* MANTLE CELL LYMPHOMA VS. PARTIAL INVOLVEMENT BY MCL

Christiane Copie-Bergman

Hopital Henri Mondor, Departement de Pathologie, Creteil, France

### LW8: *IN SITU* MANTLE CELL LYMPHOMA & CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Andrew L Feldman<sup>1</sup> and Bijayee Shrestha<sup>1</sup>

<sup>1</sup>Mayo Clinic, Dept. of Laboratory Medicine and Pathology, Rochester, MN, USA

Cases discussed by chairpersons: LW33.1, 43.1, 76.3, 79, 24, 100, 36.1, 61, 40, 55, 86, 67.2

10.30 – 10.50 Coffee break

## 10.50 – 12.50 **Session 4: Early T-cell and NK-cell lymphoproliferative lesions**

Chairs: José Cabeçadas & Philippe Gaulard

### Session 4.1: AITL and related conditions

Case presentations:

#### LW62.2: EARLY PHASE OF AITL MIMICKING FOLLICULAR LYMPHOMA

Philip Kluin<sup>1</sup>, Stefano Rosati<sup>1</sup>, Gustaaf Van Imhoff<sup>2</sup>, Ed Schuurings<sup>3</sup>, Ton Langerak<sup>4</sup> and Coen Schoots<sup>5</sup>

<sup>1</sup>UMCG, Dept Pathology & Medical Biology, Groningen, Netherlands; <sup>2</sup>UMCG, Dept Hematology, Groningen, Netherlands; <sup>3</sup>UMCG, Dept Pathology & Medical Biology, Groningen, The Netherlands; <sup>4</sup>EMCR, Dept Immunology, Rotterdam, Netherlands; <sup>5</sup>SSZOG, Dept Pathology, Winschoten, Netherlands

#### LW85.3: VARIANT OF PERIPHERAL T-CELL LYMPHOMA WITH FOLLICULAR PATTERN

Yenlin Huang<sup>1</sup> and Philippe Gaulard<sup>1</sup>

<sup>1</sup>CHU Henri Mondor, Département de Pathologie and Inserm U955, Créteil, France

Cases discussed by chairpersons: LW6, 22.4, 26, 87, 33.3, 54, 32.1, 32.2, 78.4

### Session 4.2: EATL and related conditions

**Case presentations:**

**LW101: ENTHEROPATHY-ASSOCIATED T-CELL LYMPHOMA ADJACENT TO AREAS WITH CELIAC DISEASE**

Teresa Marafioti<sup>1</sup>, Heliette Chapuis<sup>2</sup> and Philippe Gaulard<sup>1</sup>

<sup>1</sup>Inserm U955, CHU Henri Mondor, Department of Pathology, Creteil, Cedex, France; <sup>2</sup>University of Nimes, Department of Pathology, Nimes, France

**LW66.2: NK CELL ENTEROPATHY**

Elaine S Jaffe<sup>1</sup> and Adnan Mansoor<sup>2</sup>

<sup>1</sup>National Cancer Institute, Hematopathology Section, Bethesda, MD, USA

<sup>2</sup>University of Calgary, Pathology and Lab Medicine, Calgary, Canada

**LW97: TYPE II ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA**

Laurence L De Leval<sup>1</sup>, Hanifa Bouzourene<sup>1</sup> and Nicolas Ketterer<sup>2</sup>

<sup>1</sup>CHUV, Pathology, Lausanne, Switzerland; <sup>2</sup>CHUV, Hematology-Oncology, Lausanne, Switzerland

Case discussed by chairpersons: LW65

**Session 4.3: Cutaneous T-cell proliferations**

**Case presentation:**

**LW78.2: PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA**

Teresa Cardesa<sup>1</sup>, Luis Colomo<sup>1</sup> and Elias Campo<sup>1</sup>

<sup>1</sup>Hospital Clinic, Hematopathology, Barcelona, Spain

Case discussed by chairpersons: LW1

**Session 4.4: Early lesions/clonal T-cells**

**Case presentations:**

**LW34: MONOCLONAL T-LYMPHOCYTOSIS OF UNCERTAIN SIGNIFICANCE**

Socorro María Rodríguez-Pinilla<sup>1</sup>, Manuela Mollejo<sup>2</sup>, Teresa (Nam) Syong Hyun<sup>3</sup>, Santiago Montes-Moreno<sup>4</sup> and Miguel Ángel Piris<sup>5</sup>

<sup>1</sup>CNIO, Molecular Pathology, Lymphoma Group, Madrid, Spain; <sup>2</sup>Hospital

Virgen de la Salud, Pathology Department, Toledo, Spain; <sup>3</sup>Hospital de

Albacete, Pathology Department, Albacete, Spain; <sup>4</sup>CNIO, Molecular Patology,

Lymphoma Group, Madrid, Spain; <sup>5</sup>CNIO, Molecular Pathology Department,

Lymphoma Group, Madrid, Spain

**LW59: ANAPLASTIC LARGE CELL LYMPHOMA, ALK NEGATIVE, ASSOCIATED WITH BREAST IMPLANT**

Ahmet Dogan<sup>1</sup>

<sup>1</sup>Mayo Clinic, DLMP, Rochester, MN, USA

Cases discussed by chairpersons: LW76.1, 93.2

12.50 – 13.50 Lunch Break

13.50 – 15.50 **Session 5: Virus related lymphoproliferative lesions**

Chairs: Elaine Jaffe & Isinsu Kuzu

Session 5.1: EBV+ proliferations related to acute EBV infections – chronic active or progressive

Case presentations:

LW66.1: CHRONIC ACTIVE EBV DISEASE OF B CELL TYPE

Stefania Pittaluga<sup>1</sup>, Jeffrey Cohen<sup>2</sup>, Mark Raffeld<sup>1</sup> and Elaine S Jaffe<sup>1</sup>

<sup>1</sup>NIH/NCI, Bethesda, USA; <sup>2</sup>NIH/NIAID, Bethesda, USA

LW92.1: 23 MONTH-OLD HISPANIC GIRL WITH EPSTEIN-BARR VIRUS POSITIVE T-CELL LYMPHOPROLIFERATIVE DISORDER OF CHILDHOOD

Carlo M Valentino<sup>1</sup>, Deborah A Fuchs<sup>1</sup> and Lisa M Rimsza<sup>1</sup>

<sup>1</sup>University of Arizona, Department of Pathology, Tucson, United States of America

Cases discussed by chairpersons: LW80, 66.3

Session 5.2: Transplant and other iatrogenically related EBV-associated proliferations

Case presentation:

LW21.2: EARLY POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (IM-LIKE)

Lauren B Smith<sup>1</sup> and Bertram Schnitzer<sup>1</sup>

<sup>1</sup>University of Michigan, Hematopathology, Ann Arbor, Michigan, United States

Cases discussed by chairpersons: LW92.3, 69, 88, 95

Session 5.3: EBV+ proliferations with no specific risk factors, such as lymphomatoid granulomatosis

Case presentation:

LW10: LYMPHOMATOID GRANULOMATOSIS

Penka Andreeva<sup>1</sup>, Sune Eriksson<sup>1</sup>, Urban Jerlström<sup>2</sup>, Oscar Caro<sup>3</sup> and Mats Karlsson<sup>1</sup>

<sup>1</sup>University Hospital. Pathology, Örebro, Sweden; <sup>2</sup>University Hospital. Oncology, Örebro, Sweden; <sup>3</sup>University Hospital. Respiratory Medicine, Örebro, Sweden

Cases discussed by chairpersons: LW48.1, 48.2

Session 5.4: EBV+ proliferations in the elderly

Case presentation:

LW13: EARLY PHASE OF EBV RELATED LPD IN AN ELDERLY PATIENT WITH PROGRESSION TO EBV+ LARGE B-CELL LYMPHOMA

Santiago Montes-Moreno<sup>1</sup>, Sonia Garcia Hernandez<sup>2</sup>, Carmen Nieves Hernandez Leon<sup>2</sup>, Socorro Maria Rodriguez Pinilla<sup>1</sup> and Miguel Angel Piris Pinilla<sup>1</sup>

<sup>1</sup>Spanish National Cancer Center, Lymphoma Group, Molecular Pathology Program, Madrid, Spain; <sup>2</sup>Hospital Universitario de Canarias, Pathology Department, Canarias, Spain

Cases discussed by chairpersons: LW81, 90

Session 5.5: EBV+ lymphoproliferations in the setting of HIV

Cases discussed by chairpersons: LW11, 32.3, 70

Session 5.6: HHV-8 associated lymphoproliferations

Case presentations:

LW82: HHV8- ASSOCIATED MULTICENTRIC CASTLEMAN'S DISEASE IN HIV INFECTION

Anne NM Moreau<sup>1</sup>

<sup>1</sup>Hotel Dieu, Anatomie Pathologique, Nantes 44093, France

LW58: MICROLYMPHOMA ARISING IN A HIV + MAN WITH HHV-8+, EBV+ MULTICENTRIC CASTLEMAN DISEASE, PLASMA-BLASTIC TYPE

Deniz Peker<sup>1</sup>, Serhan Alkan<sup>2</sup> and Antonio Martinez<sup>1</sup>

<sup>1</sup>Mount Sinai Medical Center, Pathology, Miami Beach, USA; <sup>2</sup>Vitro Molecular Laboratories, Pathology, Miami, USA

Cases discussed by chairpersons: LW53, 75, 15, 47, 94

15:50 – 16.30 **General Discussion**

All panel members

16.30 **Closure of the Meeting**

